OncoGenex Pharmaceuticals Inc. said Wednesday it appointed Jack Goldstein to the board of directors and named him chairman, while also appointing H. Stewart Parker.
Also, the company said Martin Mattingly, CEO of Trimeris, agreed to stand for election at the company's upcoming annual general meeting.
Current board members Dwight Winstead and Michael Martino will serve on the board until the annual meeting on June 8 and are not seeking re-election.
Goldstein served as president and chief operating officer of Chiron Corp. until its acquisition by Novartis in April 2006. Parker served as president, chief executive officer and director of Targeted Genetics Corp.